drugset / Trial / NCT01325415

A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects

NCT01325415

Phase 1 Completed 45 enrolled AstraZeneca
RandomizedCrossoverDouble-blindBasic science

Summary

The purpose of this study is to evaluate the effects on QTc interval in healthy males when administered a single dose of NKTR-118 compared with placebo and moxifloxacin. (QTc is a specific time interval that can be measured in a heart beat by taking Electrocardiogram (ECG))

Timeline

Start
2011-04
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule 400 mg
Subject Naloxegol Small molecule 25 mg Oral
Subject Naloxegol Small molecule 150 mg Oral